Drug name - Kimyrsa

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(12 years from now)

IN359618B MELINTA THERAP High Purity Oritavancin And Method Of Producing Same
Jul, 2035

(12 years from now)

IN201717005135A MELINTA THERAP High Purity Oritavancin And Method Of Producing Same
Jul, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592 MELINTA THERAP Methods of treatment using single doses of oritavancin Aug, 2029

(6 years from now)

US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin Apr, 2030

(7 years from now)

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 1.2GM BASE/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.